Delegates from European Parliament Express Support for Rapid Development of New TB Vaccine
Comments expressed during tour of South African clinical trial site where Emergent’s TB vaccine candidate is expected to complete enrollment in April for its Phase IIb efficacy study
ROCKVILLE, Md., Feb 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced that a joint delegation of Members of the European Parliament (MEPs) and [...]
March 3, 2011
Tags: Clinical trial, European Parliament, South Africa, TB Vaccine, Tuberculosis, University of Oxford, Vaccination Posted in: Clinical trial, Emergent BioSolutions, TB, Vaccine, fuad el-hibri 
No Comments
Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia
ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]
February 1, 2011
Tags: American Society of Hematology, Bendamustine, Clinical trial, Emergent BioSolutions Inc., Leukemia, Leukemia & Lymphoma Society, Lymphocyte Posted in: Clinical trial, Emergent BioSolutions, Leukemia, Research and development, fuad el-hibri No Comments
Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine
ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed [...]
January 5, 2011
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, Research and development, United States Department of Health and Human Services, fuad el-hibri No Comments
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
September 20, 2010
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. Government Posted in: Anthrax vaccines, Biosolutions, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent Biosolutions Acquires Monoclonal Anthrax Product Candidate
Acquisition represents important addition to company’s portfolio of anthrax countermeasures
Emergent BioSolutions Inc. (NYSE: EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including Avanir’s lead product candidate, AVP-21D9.
AVP-21D9 is a human monoclonal antibody product candidate that is being developed as an intravenous treatment for patients [...]
July 13, 2009
Tags: Anthrax, Clinical trial, Infectious disease, Monoclonal antibodies, National Institute of Allergy and Infectious Diseases, NIAID, U.S. Food and Drug Administration, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Submits Proposal In Response To Hhs’ Rfp For Development And Procurement Of A Recombinant Protective Antigen Anthrax Vaccine
The company’s submission provides the U.S. Government with the critical option to select a domestic source to meet planned procurement of 25 million doses of rPA vaccine
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has submitted a proposal in response to a request for proposal (RFP) issued by the U.S. Department of Health and [...]
July 13, 2009
Tags: Clinical trial, Infectious disease, rPA 102, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States., US government Posted in: Uncategorized No Comments
Emergent Biosolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
Acquisition positions Emergent to offer the U.S. Government a domestic source for an advanced anthrax vaccine candidate to meet planned procurement of 25 million doses of rPA vaccine.
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product [...]
July 13, 2009
Tags: Clinical trial, Fort Detrick, Strategic National Stockpile, U.S. Food and Drug Administration, United States Department of Health and Human Services, United States., US government, VaxGen. Posted in: Uncategorized No Comments